Search results
Results from the WOW.Com Content Network
Altitude acclimatization is the process of adjusting to decreasing oxygen levels at higher elevations, in order to avoid altitude sickness. [17] Once above approximately 3,000 metres (10,000 ft) – a pressure of 70 kilopascals (0.69 atm) – most climbers and high-altitude trekkers take the "climb-high, sleep-low" approach.
High-altitude pulmonary edema (HAPE) is a life-threatening form of non-cardiogenic pulmonary edema that occurs in otherwise healthy people at altitudes typically above 2,500 meters (8,200 ft). [2] HAPE is a severe presentation of altitude sickness. Cases have also been reported between 1,500–2,500 metres or 4,900–8,200 feet in people who ...
Very high altitude = 3,500–5,500 metres (11,500–18,000 ft) Extreme altitude = above 5,500 metres (18,000 ft) Travel to each of these altitude regions can lead to medical problems, from the mild symptoms of acute mountain sickness to the potentially fatal high-altitude pulmonary edema and high-altitude cerebral edema .
CMS was first described in 1925 by Carlos Monge Medrano, a Peruvian doctor who specialised in diseases of high altitude. [3] While acute mountain sickness is experienced shortly after ascent to high altitude, chronic mountain sickness may develop only after many years of living at high altitude. In medicine, high altitude is defined as over ...
Common symptoms linked to motion sickness include nausea, fatigue, headache, irritability, dizziness, sweating and salivation, according to Cleveland Clinic. A more serious symptom of motion ...
For premium support please call: 800-290-4726 more ways to reach us
In the case of altitude sickness, where hypoxia develops gradually, the symptoms include fatigue, numbness / tingling of extremities, nausea, and cerebral hypoxia. [17] [18] These symptoms are often difficult to identify, but early detection of symptoms can be critical. [19]
An underdiagnosed deficiency of an essential mineral may be contributing to fatigue, brain fog and concentration problems in almost 1 in 4 adolescent girls and young women in the United States.